High Dose THC Can Mimic Psilocybin—And That’s a Big Deal

Bottom line: A small study suggests that 25 mg of high-dose THC may produce subjective effects similar to psilocybin, though it was associated with comparable experiences rather than proving equivalence.

A pilot study suggests that 25 mg of pure, synthetic THC can produce subjective effects that closely resemble those of psilocybin, even to someone who has used psychedelics before. The findings are coming from a small but carefully designed experiment that mirrors the conditions used in psychedelic therapy.

The Set and Setting of a Psychedelic Experience

In psychedelic research, “set and setting” is more than jargon — it’s a framework that shapes the experience. “Set” refers to the mental state of the person taking the drug, while “setting” is the environment in which it happens. Together, they can influence how a drug is felt, even more than the drug itself.

This pilot study tested whether high-dose THC could mimic psilocybin under the same conditions used in clinical psychedelic trials. Four healthy adults, aged 31 to 47, with three women, took part in a double-blind, placebo-controlled, within-subject crossover design. Each person received psilocybin, synthetic THC (dronabinol), and a whole-plant cannabis distillate extract (89.9% THC), in a random order. The researchers didn’t know which substance the participants had taken, which aimed to reduce bias.

The goal was to see if high-dose THC could produce the kind of intense, transformative experience typically associated with classic psychedelics like psilocybin. That experience usually includes vivid imagery, emotional release, and a sense of connection to the universe. It can also be overwhelming, with anxiety or paranoia.

THC Can Feel Like Psilocybin—Even to People Who Know the Difference

The results were unexpected. Both the synthetic THC (dronabinol) and the whole-plant cannabis extract, at 25 mg, produced subjective experiences similar to 25 mg of psilocybin. This was surprising because THC is usually associated with a more sedating or dissociative effect, not the intense visual and emotional experiences of classic psychedelics.

One participant, who had used psychedelics before, reported that the THC felt like a “classic hallucinogen.” Another, who had never taken one, also believed they had used a classic hallucinogen. Both were wrong — they had taken THC — but the similarity in their experiences was striking.

The researchers noted that the nature of the experience, not just its intensity, was similar to psilocybin. Participants described a sense of altered time, heightened awareness, and a shift in perspective — features that define the psychedelic experience.

The form of THC didn’t seem to matter much. Whether it was synthetic or whole-plant, the effects were similar. This suggests that potency, not source, is key to the kind of experience it produces.

But the study gets even more interesting. After each session, participants were asked what drug they thought they had taken. Both the experienced and inexperienced participants were mistaken. That’s a powerful reminder of how deeply set and setting can shape the experience.

The Science of Set and Setting: More Than Just a Buzzword

Set and setting are often dismissed as just a catchy phrase, but this study shows they can be a powerful force in shaping the effects of psychoactive substances. The same conditions used in psychedelic therapy — a quiet, comfortable environment with a trusted guide — can significantly influence how a person perceives and experiences a drug.

It’s not just about the environment. It’s about expectations, social context, and the psychological state of the person. Someone who is anxious might have a very different experience than someone who is relaxed and open. Prior knowledge of the drug can also change the experience.

These findings raise important questions about how psychoactive substances are administered. If set and setting can shape the experience so profoundly, we might need to rethink how we design the experience itself, not just the drug.

The study also raises the possibility that high-dose THC could have therapeutic applications. But the research is limited by its small sample size, and more work is needed before drawing conclusions.

Frequently Asked Questions

Q: Can THC really mimic psilocybin?
A: The study suggests that 25 mg of pure, synthetic THC and a whole-plant cannabis distillate extract (89.9% THC) can produce subjective experiences similar to 25 mg of psilocybin. Both a psychedelic-naïve and a psychedelic-experienced participant mistakenly believed they had taken a classic hallucinogen.

Q: What does this mean for the future of psychedelic therapy?
A: If THC can produce effects similar to psilocybin, it could open up new possibilities for psychedelic therapy. However, more research is needed to understand the full range of effects and potential therapeutic applications.

Q: Is this study reliable?
A: The study is a pilot, meaning it’s preliminary and has a small sample size. The results are promising, but they cannot be generalized to a larger population. More research is needed to confirm these findings.

Q: What about the role of set and setting?
A: The study highlights the importance of set and setting in shaping the experience of a psychoactive substance. The same conditions used in psychedelic therapy — such as a quiet, comfortable environment with a trusted guide — can significantly influence how a person perceives and experiences a drug.

Q: Could this lead to new treatments for mental health conditions?
A: The study raises the possibility that high-dose THC might have untapped potential in treating mental health conditions. However, more research is needed to explore this possibility.

Sources

• ¶Pilot study comparing the effects of high dose THC to high dose psilocybin and placebo in the set and setting of a classic psychedelic therapy session
• ¶Acute Pharmacological Effects of Two Synthetic Cathinones in Humans: An Observational Study of N-Ethylhexedrone and N-Ethyl-nor-pentedrone
• ¶Disposition and effects of alpha-pyrrolidinoisohexanophenone (α-PHiP) in comparison with cocaine: an observational study

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.